Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis.
Visser
K
K
Verpoort
K N
KN
van Dongen
H
H
van der Kooij
S M
SM
Allaart
C F
CF
Toes
R E M
RE
Huizinga
T W J
TW
van der Helm-van Mil
A H M
AH
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D015331:Cohort Studies; D006801:Humans; D016015:Logistic Models; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000276:immunology*; D011379:Prognosis
D018501:Antirheumatic Agents; D001323:Autoantibodies; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D008727:Methotrexate